After surgery with curative intent, most pancreatic ductal adenocarcinoma (PDAC) patients relapse from dormant disseminated tumor cells (DTCs) that already colonized distant organs. In a mouse resection model that mimics early versus latent recurrence, dormancy of these DTCs was shown to require adaptive immunity — immunodeficient nude hosts lose the dormant phenotype entirely — yet dormant cells also overexpress the circadian transcriptional repressor Dec2, which represses MHC class I antigen presentation and thereby shields them from T cells. Whether immune cells actively induce or maintain the dormant state, or merely eliminate cells that attempt to reactivate while Dec2-high cells evade surveillance, remains unresolved, as does the resulting strategic choice for therapy: maintain dormant cells in terminal quiescence, force them into senescence, or render them visible and eradicate them. The source group's own 2026 follow-up established Dec2's dual role in quiescence and immune evasion but did not settle the induction-versus-constraint question, and parallel work in breast, lung, and other pancreatic models supports competing, model-dependent answers.

Background

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer in which even patients whose primary tumor is surgically removed almost invariably develop metastatic relapse — more than 80% of resected patients — attributed to disseminated tumor cells (DTCs: single cancer cells shed from the primary tumor that lodge in distant organs such as the liver before surgery). Many of these DTCs enter dormancy, a reversible state of cell-cycle arrest in which the cell survives occult for months to years before reactivating into overt metastasis; this occult reservoir is also called minimal residual disease. Dormancy is hard to study because dormant cells are rare and non-dividing, so functional assays of tumor initiation cannot be applied to them.

A bioRxiv preprint by Dudgeon, Harris and colleagues (2020) introduced a mouse model of resectable PDAC designed to recapitulate patient outcomes: Ink4a.1 cells (a cell line derived from the p48-Cre; KrasG12D^{G12D}; p16/p19-null mouse PDAC model) are implanted orthotopically in the pancreas, the primary tumor is resected, and mice are followed long-term. About 30–35% of immunocompetent mice stay recurrence-free for hundreds of days (the dormant/latent phenotype), mirroring long-term human survivors. Single-cell transcriptomics of dormant liver DTCs showed they adopt a cancer-stem-cell-like, chemotherapy-resistant state, upregulate the transcriptional repressor Dec2 (also called BHLHE41, a circadian-clock gene), silence the mutant KrasKras allele monoallelically through promoter DNA methylation, and express immunomodulatory genes including the chemokine CCL5. A 73-gene dormancy signature correlated with DTCs isolated from patients at surgery, but did not significantly distinguish short- from long-term human survivors.

The immunological result at the heart of this problem: when the same resection experiment was performed in nude mice (which lack T cells and have dysfunctional B cells), all mice died of early recurrence — median survival 24 days versus 568 days in immunocompetent hosts — so adaptive immunity is required for the dormant phenotype in this model. Whether immunity actively induces or maintains dormancy, or merely prevents reactivation (for example by killing cells that start proliferating), was left open. This question sits in a field with contradictory indications: T cells can directly induce dormancy through cytokine signaling from the tumor-necrosis-factor receptor 1 (TNFR1) and interferon-γ\gamma (IFN-γ\gamma) in a pancreatic islet carcinogenesis model (Müller-Hermelink et al. 2008); CD39+^+PD-1+^+CD8+^+ T cells enforce metastatic dormancy in breast cancer via TNFα\alpha/IFN-γ\gamma (Tallón de Lara et al. 2021); yet in a different PDAC model, dormant liver DTCs escape immunity because unresolved endoplasmic-reticulum stress keeps MHC class I (the molecule that displays tumor-derived peptide antigens to CD8+^+ T cells) off their surface (Pommier et al. 2018).

The same group's follow-up line — preprinted in 2024 and published in Developmental Cell in 2026 as Wang et al. — established that Dec2 has a dual, dose-dependent role: it represses the proliferation gene Cdk4 (driving quiescence) and simultaneously represses multiple components of the MHC-I antigen-presentation pathway (proteasome subunits, the peptide transporter Tap1, and ‘β‘`\beta`2-microglobulin), so Dec2-high dormant cells evade T-cell recognition; deleting Dec2 repolarizes the tumor microenvironment from immunologically cold (low T-cell infiltration) to hot and improves survival after resection in an immune-dependent manner. These findings make the original question sharper rather than settled: if dormancy is a cell-intrinsic Dec2 program, it is paradoxical that dormancy disappears entirely without adaptive immunity. Reviews through 2026 continue to treat immune regulation of dormancy — and the choice between maintaining dormancy versus eradicating dormant cells — as open problems.

Problem Statement

In resection-recapitulating models of pancreatic ductal adenocarcinoma, determine how the adaptive immune system governs the dormant state of disseminated tumor cells: (i) establish whether immune cells actively induce and/or maintain dormancy of DTCs — for example through T-cell cytokine signaling of the TNFR1/TNFα/IFN-γ type shown to enforce dormancy in pancreatic islet carcinogenesis and breast cancer — or whether dormancy is a tumor-cell-intrinsic program (Dec2-driven quiescence, monoallelic mutant KRAS silencing) that the immune system merely constrains by eliminating cells that attempt to reactivate; (ii) specifically, reconcile the requirement for adaptive immunity in the Ink4a.1 resection model (dormancy is completely lost in T-cell-deficient nude hosts) with the observation that the same dormant cells evade T-cell recognition through Dec2-mediated repression of MHC-I antigen presentation; and (iii) on that mechanistic basis, establish whether any candidate strategy against minimal residual disease after PDAC resection is supported by the mechanistic evidence over the others — maintaining dormant cells in terminal quiescence, forcing them into senescence, or rendering them immunologically visible and eradicating them. Parts (i)–(iii) are complementary — the general determination, its concrete test in the Ink4a.1/Dec2 paradox, and the therapeutic conclusion that follows from them.

References

  1. Dudgeon C, Harris CR, Chen Y, Ghaddar B, Sharma A, Shah MM, Roberts AI, Casabianca A, Collisson EA, Balachandran VP, Vertino PM, De S, Carpizo DR. A Novel Model of Pancreatic Cancer Dormancy Reveals Mechanistic Insights and a Dormancy Gene Signature with Human Relevance. bioRxiv preprint, 2020. doi:10.1101/2020.04.13.037374, https://doi.org/10.1101/2020.04.13.037374
  2. Wang L, Harris CR, Dudgeon C, Prela O, Cazarin J, Shih CH, Davidson C, Casabianca A, De S, Narrow W, Becker J, Grandgenett PM, Hollingsworth MA, Grem JL, Kim M, Hong Y, Gerber S, Vertino PM, Gao C, Klamer Z, Repesh A, Hao Y, Ryan AT, Breitenbach M, Bianchi A, Datta J, Altman BJ, Haab B, Carpizo DR. The circadian gene Dec2 promotes pancreatic cancer progression and dormancy through immune evasion. Developmental Cell 61(6):1208–1222.e9, 2026. doi:10.1016/j.devcel.2026.04.001, https://doi.org/10.1016/j.devcel.2026.04.001
  3. Harris CR, Wang L, Dudgeon C, Prela O, Cazarin de Menezes J, Shih CH, Davidson C, Casabianca A, De S, Narrow W, Becker J, Balachandran VP, Grandgenett PM, Hollingsworth MA, Grem JL, Kim M, Hong Y, Gerber S, Vertino PM, Gao C, Repesh A, Klamer Z, Hao Y, Altman BJ, Haab B, Carpizo DR. The circadian gene Dec2 promotes pancreatic cancer dormancy by regulating tumor cell antigen presentation to facilitate immune evasion. bioRxiv preprint, 2024. doi:10.1101/2024.11.12.623005, https://doi.org/10.1101/2024.11.12.623005
  4. Sun T, Scheiermann C. Dec2 conceals tumors from the immune system. Developmental Cell 61(6):1167–1168, 2026. doi:10.1016/j.devcel.2026.05.007, https://doi.org/10.1016/j.devcel.2026.05.007
  5. Pommier A, Anaparthy N, Memos N, Kelley ZL, Gouronnec A, Yan R, Auffray C, Albrengues J, Egeblad M, Iacobuzio-Donahue CA, Lyons SK, Fearon DT. Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases. Science 360(6394):eaao4908, 2018. doi:10.1126/science.aao4908, https://doi.org/10.1126/science.aao4908
  6. Müller-Hermelink N, Braumüller H, Pichler B, Wieder T, Mailhammer R, Schaak K, Ghoreschi K, Yazdi A, Haubner R, Sander CA, Mocikat R, Schwaiger M, Förster I, Huss R, Weber WA, Kneilling M, Röcken M. TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 13(6):507–518, 2008. doi:10.1016/j.ccr.2008.04.001, https://doi.org/10.1016/j.ccr.2008.04.001
  7. Tallón de Lara P, Castañón H, Vermeer M, Núñez N, Silina K, Sobottka B, Urdinez J, Cecconi V, Yagita H, Movahedian Attar F, Hiltbrunner S, Glarner I, Moch H, Tugues S, Becher B, van den Broek M. CD39+PD-1+CD8+ T cells mediate metastatic dormancy in breast cancer. Nature Communications 12:769, 2021. doi:10.1038/s41467-021-21045-2, https://doi.org/10.1038/s41467-021-21045-2
  8. Goddard ET, Linde MH, Srivastava S, Klug G, Shabaneh TB, Iannone S, Grzelak CA, Marsh S, Riggio AI, Shor RE, Linde IL, Guerrero M, Veatch JR, Snyder AG, Welm AL, Riddell SR, Ghajar CM. Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies. Cancer Cell 42(1):119–134.e12, 2024. doi:10.1016/j.ccell.2023.12.011, https://doi.org/10.1016/j.ccell.2023.12.011
  9. Adam-Artigues A, Valencia Salazar LE, Aguirre-Ghiso JA. Immune evasion by dormant disseminated cancer cells: A Fermi paradox? Cancer Cell 42(1):13–15, 2024. doi:10.1016/j.ccell.2023.12.017, https://doi.org/10.1016/j.ccell.2023.12.017
  10. Wang Z, Elbanna Y, Godet I Gan S, Peters L, Lampe G, Chen Y, Xavier J, Huse M, Massagué J. TGFβ induces an atypical EMT to evade immune mechanosurveillance in lung adenocarcinoma dormant metastasis. Nature Cancer 7(1):131–149, 2026. doi:10.1038/s43018-025-01094-y, https://doi.org/10.1038/s43018-025-01094-y
  11. Grant G, Ferrer CM. The role of the immune tumor microenvironment in shaping metastatic dissemination, dormancy, and outgrowth. Trends in Cell Biology 36(5):377–391, 2026. doi:10.1016/j.tcb.2025.05.006, https://doi.org/10.1016/j.tcb.2025.05.006
  12. Aguirre-Ghiso JA. Translating the Science of Cancer Dormancy to the Clinic. Cancer Research 81(18):4673–4675, 2021. doi:10.1158/0008-5472.CAN-21-1407, https://doi.org/10.1158/0008-5472.CAN-21-1407